ethyl 2-(5-fluoro-2-methyl-1H-inden-3-yl)acetate | 53077-50-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: ethyl 2-(5-fluoro-2-methyl-1H-inden-3-yl)acetate
• 英文别名: ethyl 2-(6-fluoro-2-methyl-3H-inden-1-yl)acetate
• CAS: 53077-50-2
• 化学式: C₁₄H₁₅FO₂
• 分子量: 234.27
• InChiKey: RYKMJTNMCOIXGT-UHFFFAOYSA-N

物化性质

• 沸点：
  314.0±42.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(5-fluoro-2-methyl-1H-inden-3-yl)acetate 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium hydroxide 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 38.5h， 生成 (Z)-2-(5-fluoro-2-methyl-1-(4-(pyrid-2-yl)benzylidene)-1H-inden-3-yl)acetic acid
  参考文献：
  名称：

  Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

  摘要：

  RXR alpha represents an intriguing and unique target for pharmacologic interventions. We recently showed that Sulindac and a designed analog could bind to RXR alpha and modulate its biological activity, including inhibition of the interaction of an N-terminally truncated RXR alpha (tRXR alpha) with the p85 alpha regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K). Here we report the synthesis, testing and SAR of a series of novel analogs of Sulindac as potential modulators for inhibiting tRXR alpha-dependent AKT activation. A new compound 30 was identified to have improved biological activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.012
• 作为产物：
  描述：

  6-氟-2-甲基-1-茚酮 在 硫酸 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 8.5h， 生成 ethyl 2-(5-fluoro-2-methyl-1H-inden-3-yl)acetate
  参考文献：
  名称：

  Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

  摘要：

  RXR alpha represents an intriguing and unique target for pharmacologic interventions. We recently showed that Sulindac and a designed analog could bind to RXR alpha and modulate its biological activity, including inhibition of the interaction of an N-terminally truncated RXR alpha (tRXR alpha) with the p85 alpha regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K). Here we report the synthesis, testing and SAR of a series of novel analogs of Sulindac as potential modulators for inhibiting tRXR alpha-dependent AKT activation. A new compound 30 was identified to have improved biological activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.012

文献信息

• METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY
  申请人：Zhang Xiao-kun

  公开号：US20150266842A1

  公开（公告）日：2015-09-24

  Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenvironment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.

  本文提供了与视黄醛受体选择性通路相关的方法和组合物。如本文所述，该通路可以被定向用于操纵肿瘤微环境。例如，本文描述的方法和组合物可用于诱导癌细胞凋亡。此外，包括舒林达克及其类似物在内的本文描述的组合物可用于针对该通路治疗或预防人类患者的癌症。
• Methods and compositions related to retinoid receptor-selective pathway
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10087156B2

  公开（公告）日：2018-10-02

  Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenviroment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.

  本文提供了与视黄醇受体选择性途径有关的方法和组合物。如本文所述，该通路可作为靶向来操纵肿瘤微环境。例如，本文所述的方法和组合物可用来诱导癌细胞凋亡。此外，本文所述的组合物，包括舒林酸及其类似物，可用于靶向这一途径，治疗或预防人类患者的癌症。
• COMPOUND CONTAINING INDOLEACETIC ACID CORE STRUCTURE AND USE THEREOF
  申请人：Beijing An Jian Xi Bio-Medical Technology Co., Ltd

  公开号：EP3252039B1

  公开（公告）日：2021-11-03
• METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY
  申请人：Sanford-Burnham Medical Research Institute

  公开号：US20170313668A1

  公开（公告）日：2017-11-02

  Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenviroment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.
• US9611235B2
  申请人：——

  公开号：US9611235B2

  公开（公告）日：2017-04-04